Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897236707> ?p ?o ?g. }
- W2897236707 endingPage "2366" @default.
- W2897236707 startingPage "2353" @default.
- W2897236707 abstract "Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly allocated patients open-label in a 1:1 ratio to standard of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal anti-inflammatory drug use. Standard of care was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December, 2015. Men allocated radiotherapy received either a daily (55 Gy in 20 fractions over 4 weeks) or weekly (36 Gy in six fractions over 6 weeks) schedule that was nominated before randomisation. The primary outcome was overall survival, measured as the number of deaths; this analysis had 90% power with a one-sided α of 2·5% for a hazard ratio (HR) of 0·75. Secondary outcomes were failure-free survival, progression-free survival, metastatic progression-free survival, prostate cancer-specific survival, and symptomatic local event-free survival. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. The primary outcome analysis was by intention to treat. Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden and radiotherapy schedule. This trial is registered with ClinicalTrials.gov, number NCT00268476.Between Jan 22, 2013, and Sept 2, 2016, 2061 men underwent randomisation, 1029 were allocated the control and 1032 radiotherapy. Allocated groups were balanced, with a median age of 68 years (IQR 63-73) and median amount of prostate-specific antigen of 97 ng/mL (33-315). 367 (18%) patients received early docetaxel. 1082 (52%) participants nominated the daily radiotherapy schedule before randomisation and 979 (48%) the weekly schedule. 819 (40%) men had a low metastatic burden, 1120 (54%) had a high metastatic burden, and the metastatic burden was unknown for 122 (6%). Radiotherapy improved failure-free survival (HR 0·76, 95% CI 0·68-0·84; p<0·0001) but not overall survival (0·92, 0·80-1·06; p=0·266). Radiotherapy was well tolerated, with 48 (5%) adverse events (Radiation Therapy Oncology Group grade 3-4) reported during radiotherapy and 37 (4%) after radiotherapy. The proportion reporting at least one severe adverse event (Common Terminology Criteria for Adverse Events grade 3 or worse) was similar by treatment group in the safety population (398 [38%] with control and 380 [39%] with radiotherapy).Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer.Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis." @default.
- W2897236707 created "2018-10-26" @default.
- W2897236707 creator A5000156180 @default.
- W2897236707 creator A5007452018 @default.
- W2897236707 creator A5009101766 @default.
- W2897236707 creator A5011233738 @default.
- W2897236707 creator A5011243657 @default.
- W2897236707 creator A5011703751 @default.
- W2897236707 creator A5014097745 @default.
- W2897236707 creator A5018620241 @default.
- W2897236707 creator A5022329395 @default.
- W2897236707 creator A5024085519 @default.
- W2897236707 creator A5025921361 @default.
- W2897236707 creator A5026151822 @default.
- W2897236707 creator A5029233760 @default.
- W2897236707 creator A5030105260 @default.
- W2897236707 creator A5032518609 @default.
- W2897236707 creator A5032719534 @default.
- W2897236707 creator A5033241956 @default.
- W2897236707 creator A5033521569 @default.
- W2897236707 creator A5034586479 @default.
- W2897236707 creator A5042462233 @default.
- W2897236707 creator A5048796030 @default.
- W2897236707 creator A5048994559 @default.
- W2897236707 creator A5049996683 @default.
- W2897236707 creator A5052395575 @default.
- W2897236707 creator A5054862904 @default.
- W2897236707 creator A5059261043 @default.
- W2897236707 creator A5060916908 @default.
- W2897236707 creator A5060969562 @default.
- W2897236707 creator A5061256858 @default.
- W2897236707 creator A5061571348 @default.
- W2897236707 creator A5064442357 @default.
- W2897236707 creator A5065195021 @default.
- W2897236707 creator A5066122486 @default.
- W2897236707 creator A5073038301 @default.
- W2897236707 creator A5075073881 @default.
- W2897236707 creator A5075388907 @default.
- W2897236707 creator A5079820994 @default.
- W2897236707 creator A5082736524 @default.
- W2897236707 creator A5085561716 @default.
- W2897236707 creator A5088338989 @default.
- W2897236707 creator A5088951258 @default.
- W2897236707 creator A5091666679 @default.
- W2897236707 date "2018-12-01" @default.
- W2897236707 modified "2023-10-15" @default.
- W2897236707 title "Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial" @default.
- W2897236707 cites W1591957995 @default.
- W2897236707 cites W1971992633 @default.
- W2897236707 cites W1980472079 @default.
- W2897236707 cites W2001933720 @default.
- W2897236707 cites W2010840107 @default.
- W2897236707 cites W2021256410 @default.
- W2897236707 cites W2043945205 @default.
- W2897236707 cites W2049136550 @default.
- W2897236707 cites W2073140442 @default.
- W2897236707 cites W2102032555 @default.
- W2897236707 cites W2108247235 @default.
- W2897236707 cites W2116661424 @default.
- W2897236707 cites W2146530991 @default.
- W2897236707 cites W2146599397 @default.
- W2897236707 cites W2147509995 @default.
- W2897236707 cites W2150865892 @default.
- W2897236707 cites W2151981428 @default.
- W2897236707 cites W2154323253 @default.
- W2897236707 cites W2171035654 @default.
- W2897236707 cites W2210989209 @default.
- W2897236707 cites W2214621962 @default.
- W2897236707 cites W2463183688 @default.
- W2897236707 cites W2465092116 @default.
- W2897236707 cites W2620746860 @default.
- W2897236707 cites W2620798309 @default.
- W2897236707 cites W2622408479 @default.
- W2897236707 cites W2743936472 @default.
- W2897236707 cites W2788160989 @default.
- W2897236707 cites W2805060661 @default.
- W2897236707 cites W2894350218 @default.
- W2897236707 doi "https://doi.org/10.1016/s0140-6736(18)32486-3" @default.
- W2897236707 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6269599" @default.
- W2897236707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30355464" @default.
- W2897236707 hasPublicationYear "2018" @default.
- W2897236707 type Work @default.
- W2897236707 sameAs 2897236707 @default.
- W2897236707 citedByCount "789" @default.
- W2897236707 countsByYear W28972367072018 @default.
- W2897236707 countsByYear W28972367072019 @default.
- W2897236707 countsByYear W28972367072020 @default.
- W2897236707 countsByYear W28972367072021 @default.
- W2897236707 countsByYear W28972367072022 @default.
- W2897236707 countsByYear W28972367072023 @default.
- W2897236707 crossrefType "journal-article" @default.
- W2897236707 hasAuthorship W2897236707A5000156180 @default.
- W2897236707 hasAuthorship W2897236707A5007452018 @default.
- W2897236707 hasAuthorship W2897236707A5009101766 @default.
- W2897236707 hasAuthorship W2897236707A5011233738 @default.
- W2897236707 hasAuthorship W2897236707A5011243657 @default.
- W2897236707 hasAuthorship W2897236707A5011703751 @default.
- W2897236707 hasAuthorship W2897236707A5014097745 @default.